Share on StockTwits

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc 1,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 9th. The was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

RGLS has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Regulus Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, June 17th. They now have a $7.80 price target on the stock. Finally, analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $14.76.

Regulus Therapeutics (NASDAQ:RGLS) traded down 0.91% on Friday, hitting $6.50. The stock had a trading volume of 40,353 shares. Regulus Therapeutics has a one year low of $5.40 and a one year high of $12.42. The stock has a 50-day moving average of $7.32 and a 200-day moving average of $8.10. The company’s market cap is $281.8 million.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.16. On average, analysts predict that Regulus Therapeutics will post $-0.84 earnings per share for the current fiscal year.

Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.